Four pharmaceutical companies, Kenilworth, NJ-based Schering-Plough Corp; The Procter and Gamble Co., Cincinnati; Eli Lilly and Co., Indianapolis; and Abbott Laboratories, Abbott Park, IL, were named to Fortune magazine's list of "50 Best Companies for Minorities." The list was published in the July 9 issue of the magazine.
Four pharmaceutical companies, Kenilworth, NJ-based Schering-Plough Corp; The Procter and Gamble Co., Cincinnati; Eli Lilly and Co., Indianapolis; and Abbott Laboratories, Abbott Park, IL, were named to Fortune magazine's list of "50 Best Companies for Minorities." The list was published in the July 9 issue of the magazine.
To compile the ranking, Fortune, in conjunction with the nonprofit Center for Responsibility in Business, surveyed all Fortune 1,000 companies and the 200 largest privately held firms. Companies were judged on their overall diversity programs, numbers of minority workers, employees having career goals related to minorities, numbers of future minority management candidates, implementation of a formal mentoring program for minorities, level of purchasing from minority-owned firms, and charitable contributions for programs or organizations that primarily benefit minorities.
"Fostering a diverse and inclusive workplace is essential for Abbott's success," said Miles D. White, chairman and chief executive officer of Abbott Laboratories, which appears on the list for the fourth consecutive year. "Embracing diversity cultivates an innovative and inspiring environment for our employees and our business."
The survey also compared each company's overall turnover rate with that of non-minorities and assessed how well minorities are represented in management versus the total work force.
"A commitment to work force diversity is an important responsibility of every manager at Schering-Plough," said John P. Ryan, senior vice president, human resources of Schering-Plough. "This commitment encompasses not only our recruiting efforts, but also our ongoing efforts to challenge employees of both genders and all nationalities and races to achieve their full potential through career development and job opportunities." PR
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.